<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794492</url>
  </required_header>
  <id_info>
    <org_study_id>223KT17017</org_study_id>
    <nct_id>NCT03794492</nct_id>
  </id_info>
  <brief_title>Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome</brief_title>
  <official_title>Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome: Open-label, Multi-center, Single Arm, Phase 4 Trial (DoSAKOM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of My-Rept® (Mycophenolate Mofetil 500mg/Tab. or 250mg/Cap.) in
      Combination with Tacrolimus, Methylprednisolone, Simulect in Kidney Transplant Patients
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2018</start_date>
  <completion_date type="Anticipated">November 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DSA(Donor-specific Anti-HLA Antibody)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Kidney Transplant Patients</condition>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</intervention_name>
    <description>Mycophenolate mofetil 1,000 ~ 2,000mg</description>
    <arm_group_label>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</arm_group_label>
    <other_name>Mycophenolate mofetil 1,000 ~ 2,000mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus</description>
    <arm_group_label>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone/prednisone</intervention_name>
    <description>Methylprednisolone/prednisone</description>
    <arm_group_label>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simulect® (Basiliximab)</intervention_name>
    <description>Simulect® (Basiliximab)</description>
    <arm_group_label>Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 20 years old(male or female)

          2. Patients who are planning to receive a kidney from a deceased or a living
             non-related/related donor

          3. Agreement with written informed consent

        Exclusion Criteria:

          1. Patient who receive a kidney from a related donor who showed HLA-0 mismatch
             (identical)

          2. Undergo desensitization therapy with high sensitization

          3. Patient with dual kidney transplantation recipient or have history of other organ
             transplantation in past or current.

          4. Patient who receive extra-renal solid organ or bone marrow stem cell transplantation.

          5. Patient who receive kidney transplantation from non-heart beating cadaveric
             donor(organ donor after cardiac death

          6. Patient who receive kidney transplantation from ABO blood type mismatching donor or
             lymphocyte cross matching (LCM) positive donor.

          7. Patient with cancer within 5 years, except cured skin cancer patient(Squamous cell or
             basal cell carcinoma or Early stage Renal cell carcinoma or Thyroid Cancer)

          8. Positive in serology test(HIV, HBsAg, HCV) in recipients and/or donor.

          9. Defined by the following laboratory parameters before screening period

               -  Treatment with active liver disease or Liver function test(T-bilirubin, AST, ALT,
                  ALP)is over 3 times than upper normal limit

               -  ANC &lt; 1,500/mm^3, or WBC &lt; 2,500/mm^3, or Platelet &lt; 50,000/mm^3

         10. Acute (within 4 weeks) or chronic(need to treatments) allergic/hypersensitivity
             reaction in the history of Investigational drugs (ex, mycophenolate acid or
             tacrolimus, etc.) or additives.

         11. Administration of other Investigational drugs and/or immunosuppressants within 30days
             before screening period (except allowed immunosuppressants in protocol)

         12. Women in pregnant or breast-feeding or don't using adequate contraception.

         13. Patient has conversation impairment because alcohol or drugs addiction history within
             6months or mental illness, etc.

         14. In investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Kwan Oh, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

